Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for relapsing forms of multiple sclerosis:
- Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (2026) NICE technology appraisal guidance 1126
- Cladribine for treating active relapsing forms of multiple sclerosis (2025) NICE technology appraisal guidance 1053
- Ublituximab for treating relapsing multiple sclerosis (2024) NICE technology appraisal guidance 1025
This page was last updated: